Cardiomyocyte death induced by ischaemic/hypoxic stress is differentially affected by distinct purinergic P2 receptors

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 5, 2012, Pages 1074-1084

  Cosentino, Simona ^a   Banfi, Cristina ^a   Burbiel, Joachim C ^b   Luo, Haijian ^a,c   Tremoli, Elena ^a,c   Abbracchio, Maria P ^a,c  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; Cardiomyocytes; Ischaemic hypoxic stress; P2 receptors

Indexed keywords

ADENOSINE TRIPHOSPHATE; APYRASE; HISTONE; PURINERGIC P2 RECEPTOR; PURINERGIC P2 RECEPTOR ANTAGONIST;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; DNA FRAGMENTATION; DRUG EFFECT; GENE SILENCING; GENETICS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; MOUSE; PATHOLOGY; PHYSIOLOGY; SECRETION;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; APYRASE; CELL LINE; CELLS, CULTURED; DNA FRAGMENTATION; GENE SILENCING; HISTONES; MICE; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2;

EID: 84860327813     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01382.x     Document Type: Article

References (54)

1. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology. 1997; 36: 1127-39.
2. Abbracchio MP, Burnstock G, Boeynaems JM, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006; 58: 281-341.
3. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998; 50: 413-92.
4. Brunschweiger A, Mller CE. P2 receptors activated by uracil nucleotides-an update. Curr Med Chem. 2006; 13: 289-312.
5. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 2008; 4: 1-20.
6. Pelleg A, Vassort G. P2 receptors in the cardiovascular system. In: Abbracchio MP, Williams M, editors. Purinergic and pyrimidergic signalling II. Berlin/Heidelberg: Springer-Verlag; 2001: 73-100.
7. Drury AN, Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol. 1929; 68: 213-37.
8. Bogdanov Y, Rubino A, Burnstock G. Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. Life Sci. 1998; 62: 697-703.
9. Vassort G. Adenosine 5′-triphosphate: a P2-purinergic agonist in the myocardium. Physiol Rev. 2001; 81: 767-806.
10. Wihlborg AK, Balogh J, Wang L, et al. Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ Res. 2006; 98: 970-6.
11. Banfi C, Ferrario S, De Vincenti O, et al. P2 receptors in human heart: upregulation of P2 χ 6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death. J Mol Cell Cardiol. 2005; 39: 929-39.
12. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004; 240: 31-304.
13. Leybaert L, Braet K, Vandamme W, et al. Connexin channels, connexin mimetic peptides and ATP release. Cell Commun Adhes. 2003; 10: 251-7.
14. Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett. 2004; 572: 65-8.
15. Dutta AK, Sabirov RZ, Uramoto H, et al. Role of ATP-conductive anion channel in ATP release from neonatal rat cardiomyocytes in ischaemic or hypoxic conditions. J Physiol. 2004; 559: 799-812.
16. Yitzhaki S, Shneyvays V, Jacobson KA, et al. Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. Biochem Pharmacol. 2005; 69: 1215-23.
17. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol. 2004; 286: H823-9.
18. Mazzola A, Amoruso E, Beltrami E, et al. Opposite effects of uracil and adenine nucleotides on the survival of murine cardiomyocytes. J Cell Mol Med. 2008; 12: 522-36.
19. Claycomb WC, Lanson NAJr., Stallworth BS, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A. 1998; 95: 2979-84.
20. Banfi C, Brioschi M, Barcella S, et al. Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells. J Thromb Haemost. 2007; 5: 2437-44.
21. Ceruti S, Franceschi C, Barbieri D, et al. Apoptosis induced by 2-chloro-adenosine and 2-chloro-2'-deoxy-adenosine in a human astrocytoma cell line: differential mechanisms and possible clinical relevance. J Neurosci Res. 2000; 60: 388-400.
22. Ceruti S, Beltrami E, Matarrese P, et al. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. Mol Pharmacol. 2003; 63: 1437-47.
23. Jacobson KA, Costanzi S, Joshi BV, et al. Agonists and antagonists for P2 receptors. Novartis Found Symp. 2006; 276: 58-68.
24. North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002; 82: 1013-67.
25. Abbracchio MP, Verderio C. Pathophysiological roles of P2 receptors in glial cells. Novartis Found Symp. 2006; 276: 91-103.
26. Jarvis MF, Khakh BS. ATP-gated P2X cation-channels. Neuropharmacology. 2009; 56: 208-15.
27. Jacobson KA, Ivanov AA, de Castro S, et al. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009; 5: 75-89.
28. Mamedova LK, Joshi BV, Gao ZG, et al. Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004; 67: 1763-70.
29. Govindaraju V, Martin JG, Maghni K, et al. The effects of extracellular purines and pyrimidines on human airway smooth muscle cells. J Pharmacol Exp Ther. 2005; 315: 941-8.
30. Kuzmin AI, Lakomkin VL, Kapelko VI, et al. Interstitial ATP level and degradation in control and postmyocardial infarcted rats. Am J Physiol. 1998; 275: C766-71.
31. Dutta AK, Sabirov RZ, Uramoto H, et al. Role of ATP-conductive anion channel in ATP release from neonatal rat cardiomyocytes in ischaemic or hypoxic conditions. J Physiol. 2004; 559: 799-812.
32. Hayashi S, Hazama A, Dutta AK, et al. Detecting ATP release by a biosensor method. Sci STKE. 2004; 258: pl14.
33. Schrier SM, Florea BI, Mulder GJ, et al. Apoptosis induced by extracellular ATP in the mouse neuroblastoma cell line N1E-115: studies on involvement of P2 receptors and adenosine. Biochem Pharmacol. 2002; 63:1119-26.
34. Delarasse C, Gonnord P, Galante M, et al. Neural progenitor cell death is induced by extracellular ATP via ligation of P2χ7 receptor. J Neurochem. 2009; 109: 846-57.
35. Placido R, Auricchio G, Falzoni S, et al. P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability. Cell Immunol. 2006; 244: 10-8.
36. Lepine S, Le Stunff H, Lakatos B, et al. ATP-induced apoptosis of thymocytes is mediated by activation of P2χ7 receptor and involves de novo ceramide synthesis and mitochondria. Biochim Biophys Acta. 2006; 1761: 73-82.
37. Sugimoto S, Lin X, Lai J, et al. Apyrase treatment prevents ischaemia-reperfusion injury in rat lung isografts. J Thorac Cardiovasc Surg. 2009; 138: 752-9.
38. Kittel A, Kiss AL, Müllner N, et al. Expression of NTPDase1 and caveolins in human cardiovascular disease. Histochem Cell Biol. 2005; 124: 51-9.
39. Clarke TC, Williams OJ, Martin PE, et al. ATP release by cardiac myocytes in a simulated ischaemia model: inhibition by a connexin mimetic and enhancement by an antiarrhythmic peptide. Eur J Pharmacol. 2009; 605: 9-14.
40. Hou M, Malmsjö M, Möller S, et al. Increase in cardiac P2χ1- and P2Y2-receptor mRNA levels in congestive heart failure. Life Sci. 1999; 65: 1195-206.
41. Wang ZX, Nakayama T, Sato N, et al. Association of the purinergic receptor P2Y, G-protein coupled, 2 (P2RY2) gene with myocardial infarction in Japanese men. Circ J. 2009; 73: 2322-9.
42. Braun OO, Lu D, Aroonsakool N, et al. Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors. J Mol Cell Cardiol. 2010; 49: 362-9.
43. Baraldi PG, Di Virgilio F, Romagnoli R. Agonists and antagonists acting at P2χ7 receptor. Curr Top Med Chem. 2004; 4: 1707-17.
44. Roman S, Cusdin FS, Fonfria E, et al. Cloning and pharmacological characterization of the dog P2χ7 receptor. Br J Pharmacol. 2009; 158: 1513-26.
45. Eslick GD, Thampan BV, Nalos M, et al. Circulating interleukin-18 concentrations and a loss-of-function P2χ7 polymorphism in heart failure. Int J Cardiol. 2009; 137: 81-3.
46. Vessey DA, Li L, Kelley M. Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischaemic pre- and postconditioning. J Cardiovasc Pharmacol Ther. 2010; 15: 190-5.
47. Yitzhaki S, Shainberg A, Cheporko Y, et al. Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem Pharmacol. 2006; 72: 949-55.
48. Yitzhaki S, Hochhauser E, Porat E, et al. Uridine-5'-triphosphate (UTP) maintains cardiac mitochondrial function following chemical and hypoxic stress. J Mol Cell Cardiol. 2007; 43: 653-62.
49. Shainberg A, Yitzhaki S, Golan O, et al. Involvement of UTP in protection of cardiomyocytes from hypoxic stress. Can J Physiol Pharmacol. 2009; 87: 287-99.
50. Nishida M, Sato Y, Uemura A, et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008; 27: 3104-15.
51. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5: 247-64.
52. Golembiowska K, Dziubina A. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology. 2004; 47: 414-26.
53. Goldenberg I, Shainberg A, Jacobson KA, et al. Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. Mol Cell Biochem. 2003; 252: 133-9.
54. Ji X, Kim YC, Ahern DG, et al. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol. 2001; 61: 657-63.